These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 25476783)

  • 21. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poverty, health & intellectual property rights with special reference to India.
    Satyanarayana K; Srivastava S
    Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 28478430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical researchers and the pharmaceutical industry].
    ten Cate JW
    Ned Tijdschr Geneeskd; 1999 Jun; 143(26):1349-52. PubMed ID: 10416490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity.
    Diependaele L; Cockbain J; Sterckx S
    Dev World Bioeth; 2017 Apr; 17(1):11-21. PubMed ID: 26818105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Intellectual property rights and right of access to medicines].
    Velásquez G
    Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmaceutical industry as a medicines provider.
    Henry D; Lexchin J
    Lancet; 2002 Nov; 360(9345):1590-5. PubMed ID: 12443614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
    Velasquez G
    Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonconsensual clinical trials: a foreseeable risk of offshoring under global corporatism.
    Spielman B
    J Bioeth Inq; 2015 Mar; 12(1):101-6. PubMed ID: 25630592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceuticalisation and ethical review in South Asia: issues of scope and authority for practitioners and policy makers.
    Simpson B; Khatri R; Ravindran D; Udalagama T
    Soc Sci Med; 2015 Apr; 131():247-54. PubMed ID: 24768272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Critical analysis of valuation and strategical orientation of merger and acquisition deals in the pharmaceutical industry.
    Dierks RML; Bruyère O; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):147-160. PubMed ID: 29243501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Access to vaccine technologies in developing countries: Brazil and India.
    Milstien JB; Gaulé P; Kaddar M
    Vaccine; 2007 Nov; 25(44):7610-9. PubMed ID: 17913312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outsourcing lead optimisation--the quiet revolution.
    Clark DE; Newton CG
    Drug Discov Today; 2004 Jun; 9(11):492-500. PubMed ID: 15149625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
    Baker BK
    Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intellectual property rights, market competition and access to affordable antiretrovirals.
    Pascual F
    Antivir Ther; 2014; 19 Suppl 3():57-67. PubMed ID: 25309984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current practice and perspectives in CRO oversight based on a survey performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Hennig M; Hundt F; Busta S; Mikus S; Sanden PH; Sörgel A; Ruppert T
    Ger Med Sci; 2017; 15():Doc02. PubMed ID: 28163667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.